Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Size Likely To Evolve From 2025 Through 2034?
The programmed death (PD)-1 non-small cell lung cancer market size has experienced substantial growth in recent years. It is projected to expand from $25.23 billion in 2024 to $27.50 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.0%. The growth observed in the historic period can be attributed to the increasing prevalence of non-small cell lung cancer, rising adoption of immunotherapy in developed nations, growing awareness about cancer screening, increasing approvals for monoclonal antibodies, and rising healthcare expenditure.
The market size for programmed death (PD)-1 non-small cell lung cancer is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $38.26 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include greater investments in infrastructure dedicated to cancer treatment, improved patient accessibility to biologics within developing markets, an expanding global elderly population, enhanced reimbursement provisions for immunotherapies, and a rise in the clinical efficacy of PD-1 inhibitors. Key trends anticipated for the forecast period encompass technological progress in biomarker assessments, the evolution of combination immunotherapy approaches, significant spending on individualized treatment plans, continued research and development into new PD-1 inhibitors, and pioneering efforts in immune checkpoint blockade mechanisms.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
What Are The Main Drivers Boosting The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry’s Expansion?
The programmed death (PD)-1 non-small cell lung cancer market is anticipated to expand due to the growing acceptance of personalized treatments. These treatments involve medical strategies customized to a person’s unique genetic makeup, way of life, and particular disease features, aiming for more precise and impactful results. The escalating need for personalized therapies stems from the wider accessibility of genomic profiling and biomarker testing, technologies that facilitate the identification of specific mutations and biological indicators, thereby enabling healthcare professionals to choose treatments more effective for individual patients. In the context of programmed death (PD)-1 non-small cell lung cancer (NSCLC), personalized treatments are beneficial as they customize therapies according to a patient’s genetic profile, tumor attributes, and immune system response. An example illustrates this trend: in February 2024, the US Food and Drug Administration (FDA) sanctioned 16 novel personalized treatments for rare conditions in 2023, an increase from 6 in 2022, as reported by the US-based non-profit, Personalized Medicine Coalition. Consequently, the expanding use of personalized treatments is propelling the growth of the programmed death (PD)-1 non-small cell lung cancer market.
What Are The Primary Types Of Segments Analyzed In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
Which Competitive Trends Are Defining The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Structure?
Major companies within the programmed death (PD)-1 non-small cell lung cancer market are concentrating on performing clinical trials for innovative treatments, such as monotherapy, with the goal of improving patient outcomes. Monotherapy refers to a treatment strategy that employs a single medication or therapeutic method to address a disease or condition. For example, in March 2025, Akeso, Inc., a biopharmaceutical firm based in China, reported promising findings from its Phase III HARMONi-2 trial, which evaluated Ivonescimab (AK112) combined with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC). This study successfully achieved its primary objective by notably extending progression-free survival when compared to pembrolizumab, thereby emphasizing the therapeutic capability of the dual-targeted bispecific antibody.
Who Are The Prominent Global Companies Shaping The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry?
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp
Browse Through More Reports Similar to the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market 2025, By The Business Research Company
Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Global Market Report 2025
Non Small Cell Lung Cancer Nsclc Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model